Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe UK GBp

Smith & Nephew plc (SNL.XC)

Compare
974.60
+7.60
+(0.79%)
At close: April 11 at 4:29:49 PM GMT+1
Loading Chart for SNL.XC
  • Previous Close 967.00
  • Open 957.80
  • Bid 974.40 x --
  • Ask 974.60 x --
  • Day's Range 957.80 - 979.80
  • 52 Week Range 911.00 - 1,244.75
  • Volume 773,198
  • Avg. Volume 529,098
  • Market Cap (intraday) 8.53B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) 2,707.22
  • EPS (TTM) 0.36
  • Earnings Date Feb 25, 2025
  • Forward Dividend & Yield 0.29 (2.97%)
  • Ex-Dividend Date Mar 27, 2025
  • 1y Target Est --

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com

17,349

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SNL.XC

View More

Performance Overview: SNL.XC

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

SNL.XC
1.48%
FTSE 100 (^FTSE)
2.55%

1-Year Return

SNL.XC
0.44%
FTSE 100 (^FTSE)
0.51%

3-Year Return

SNL.XC
20.23%
FTSE 100 (^FTSE)
4.54%

5-Year Return

SNL.XC
37.47%
FTSE 100 (^FTSE)
36.31%

Compare To: SNL.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SNL.XC

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    8.53B

  • Enterprise Value

    10.61B

  • Trailing P/E

    26.94

  • Forward P/E

    11.83

  • PEG Ratio (5yr expected)

    0.84

  • Price/Sales (ttm)

    1.91

  • Price/Book (mrq)

    2.10

  • Enterprise Value/Revenue

    2.37

  • Enterprise Value/EBITDA

    11.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.09%

  • Return on Assets (ttm)

    5.45%

  • Return on Equity (ttm)

    7.86%

  • Revenue (ttm)

    5.81B

  • Net Income Avi to Common (ttm)

    412M

  • Diluted EPS (ttm)

    0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    619M

  • Total Debt/Equity (mrq)

    63.08%

  • Levered Free Cash Flow (ttm)

    565.12M

Research Analysis: SNL.XC

View More

Company Insights: SNL.XC

Research Reports: SNL.XC

View More

People Also Watch